ReviewBritish journal of pharmacology2007
Taking the time to study competitive antagonism.
Review in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 102 citations in OpenAlex.
- Monovalent cations differentially regulate the activity of eukaryotic fluoride channels and impact fluoride resistance.PLoS biology · 2026Article
- In vitro confirmation of estrogenic and antiandrogenic pesticide bioactivity using schild regression analysis.Toxicology and applied pharmacology · 2025Article
- Quetiapine competitively inhibits 5-HTThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Article
- Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.British journal of pharmacology · 2024Article
- Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL.Clinical and translational science · 2023Article
- Membrane Permeabilization and Antimicrobial Activity of Recombinant Defensin-d2 and Actifensin against Multidrug-ResistantMolecules (Basel, Switzerland) · 2022Article
- The dopamine transporter antiports potassium to increase the uptake of dopamine.Nature communications · 2022Article
- Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.Pharmacological reviews · 2021Review
- Deciphering the Interaction between Neonatal Fc Receptor and Antibodies Using a Homogeneous Bioluminescent Immunoassay.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Neuroregulatory role of ginkgolides.Molecular biology reports · 2021Review
- Predicting the Activation of the Androgen Receptor by Mixtures of Ligands Using Generalized Concentration Addition.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
- Allosteric Antagonism of the ACells · 2020Article
- The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist.Frontiers in pharmacology · 2020Article
- MHC-I peptide binding activity assessed by exchange after cleavage of peptide covalently linked to β2-microglobulin.Analytical biochemistry · 2019Article
- A triad of residues is functionally transferrable between 5-HTThe Journal of biological chemistry · 2018Article
- Mechanisms and the clinical relevance of complex drug-drug interactions.Clinical pharmacology : advances and applications · 2018Review
- Distinct Signaling Patterns of Allosteric Antagonism at the P2YMolecular pharmacology · 2017Article
- Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.The Journal of pharmacology and experimental therapeutics · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Selective receptor antagonists are one of the most powerful resources in a pharmacologist's toolkit and are essential for the identification and classification of receptor subtypes and dissecting their roles in normal and abnormal body function. However, when the actions of antagonists are measured inappropriately and misleading results are reported, confusion and wrong interpretations ensue. This article gives a general overview of Schild analysis and the method of determining antagonist equilibrium constants. We demonstrate why this technique is preferable in the study of competitive receptor antagonism than the calculation of antagonist concentration that inhibit agonist-evoked responses by 50%. In addition we show how the use of Schild analysis can provide information on the outcome of single amino acid mutations in structure-function studies of receptors. Finally, we illustrate the need for caution when studying the effects of potent antagonists on synaptic transmission where the timescale of events under investigation is such that ligands and receptors never reach steady-state occupancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.